During this time, many advances were made in the areas of gene transfer efficiency and safety, and clinical development of gene therapies for hemophilia A resumed more than a decade later with AAV-fVIII vectors taking the lead into clinical trials [for review, see (43)]. Here, F8 is linked to hemophilia A.